ArticleCVIR endovascular2025
Prospective analysis of bleomycin electrosclerotherapy for clinical outcome and volume reduction in therapy refractory slow-flow malformations.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSlow-flow vascular malformations are persistent congenital vascular lesions that progressively disrupt tissue structure and function, often causing pain, swelling, and esthetic concerns. Despite the availability of surgical and sclerotherapy-based interventions, treatment outcomes are often unsatisfactory, with high rates of recurrence and resistance. The aim of this study was to prospectively evaluate the safety and effectiveness of bleomycin electrosclerotherapy in reducing lesion volume, alleviating symptoms, and improving clinical outcomes in 33 patients with slow-flow vascular malformations resistant to previous treatments. The prospective design allowed real-time observation of patients' responses to therapy, while the longitudinal follow-up, beginning with recruitment in 2020 and continuing through the end of 2024, allowed comprehensive monitoring of outcomes.
resultsAfter one treatment session, 33 of 35 (94.3%) lesions demonstrated symptomatic improvement, and all lesions (n = 35/35, 100%) showed a reduction in volume. Average volume decreased from 1781.1 to 1335.0 mL (25.0%) after one session and 1189.13 mL (33.24%) after final treatment. Mild adverse events, including redness (n = 4) and swelling (n = 25), resolved within 4 weeks. Skin changes like hyperpigmentation (n = 3) and livid discoloration (n = 4) could be observed for longer periods of time.
conclusionsBleomycin electrosclerotherapy demonstrated high effectiveness and safety for treating slow-flow malformations, establishing it as a promising therapeutic option even for lesions that have responded insufficiently to previous treatment attempts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.